TLDR DRCT surges 24% as Colossus SSP launches 2025 Momentum creator program Direct Digital’s stock jumps on Colossus SSP’s push for media diversity DRCT gains big with Colossus SSP’s new Momentum initiative for creators Colossus SSP powers DRCT rise with 2025 Momentum program announcement DRCT rallies on Colossus SSP’s inclusive publisher growth program launch Direct [...] The post Direct Digital Holdings (DRCT) Stock: Surges 24% as Colossus SSP Launches 2025 Momentum Program Empowering Independent Creators appeared first on CoinCentral.TLDR DRCT surges 24% as Colossus SSP launches 2025 Momentum creator program Direct Digital’s stock jumps on Colossus SSP’s push for media diversity DRCT gains big with Colossus SSP’s new Momentum initiative for creators Colossus SSP powers DRCT rise with 2025 Momentum program announcement DRCT rallies on Colossus SSP’s inclusive publisher growth program launch Direct [...] The post Direct Digital Holdings (DRCT) Stock: Surges 24% as Colossus SSP Launches 2025 Momentum Program Empowering Independent Creators appeared first on CoinCentral.

Direct Digital Holdings (DRCT) Stock: Surges 24% as Colossus SSP Launches 2025 Momentum Program Empowering Independent Creators

2025/10/10 04:26
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

TLDR

  • DRCT surges 24% as Colossus SSP launches 2025 Momentum creator program
  • Direct Digital’s stock jumps on Colossus SSP’s push for media diversity
  • DRCT gains big with Colossus SSP’s new Momentum initiative for creators
  • Colossus SSP powers DRCT rise with 2025 Momentum program announcement
  • DRCT rallies on Colossus SSP’s inclusive publisher growth program launch

Direct Digital Holdings (Nasdaq: DRCT) saw a sharp 24% increase in its share price, peaking at $0.3610 during Thursday’s trading.

Direct Digital Holdings (Nasdaq: DRCT)

The stock climbed rapidly in mid-morning but later gave back some gains before stabilizing near the close. This movement coincided with a key announcement from its subsidiary, Colossus SSP.

Colossus SSP introduced the 2025 class of its Momentum program, which aims to empower independent publishers and content creators. The initiative includes collaboration with Digitas, a recognized global marketing agency that has long supported inclusive media strategies. As the stock surged, the market clearly responded to the expanded commitment to innovation and industry equity.

The Momentum program is an annual initiative that supports underrepresented and high-growth digital media publishers entering the programmatic space. It aligns with DRCT’s broader strategy of increasing media diversity while strengthening its advertising infrastructure. The timing of this launch appears to have triggered heightened market activity around DRCT.

Colossus SSP Unveils 2025 Momentum Program to Support Independent Media Creators

Colossus SSP launched the new Momentum class with a structured program focused on growth for independent digital publishers. Participants will receive hands-on training in programmatic advertising, including media quality, data handling, and direct brand engagement. The company will also provide access to exclusive marketplace opportunities for creators who complete the program.

The Momentum private marketplace offers premium ad inventory and enables stronger agency-publisher relationships outside the open exchange. By enhancing visibility and monetization options, Colossus aims to bridge gaps that many independent creators face. The initiative is designed to foster long-term, sustainable media partnerships.

The 2025 class officially begins in Q4 2025, with applications still open and publisher selections to be announced shortly. DRCT’s commitment to equitable access in media has been a consistent theme in its platform strategy. This program continues that approach by giving creators the tools needed to thrive within a competitive digital ecosystem.

Direct Digital Holdings Strengthens Dual-Side Ad Strategy Through Colossus SSP and Orange 142

Direct Digital Holdings operates a combined buy- and sell-side strategy through its Colossus SSP and Orange 142 platforms. This dual approach allows the company to deliver performance-based results for both advertisers and publishers. It also generates billions of ad impressions across display, in-app, and CTV media.

Colossus SSP powers the sell-side by scaling media access across multicultural and general markets. Orange 142 offers data-optimized buying solutions for sectors including healthcare, travel, and finance. Together, these platforms create a comprehensive ecosystem that supports both mid-market clients and independent creators.

DRCT further strengthens its market position by promoting inclusive innovation. While market volatility remains a factor, the strategic alignment between Colossus and Orange 142 continues to drive measurable performance. The stock’s surge reflects confidence in this integrated advertising model and the new growth opportunities ahead.

 

The post Direct Digital Holdings (DRCT) Stock: Surges 24% as Colossus SSP Launches 2025 Momentum Program Empowering Independent Creators appeared first on CoinCentral.

Market Opportunity
EPNS Logo
EPNS Price(PUSH)
$0.012023
$0.012023$0.012023
+1.11%
USD
EPNS (PUSH) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09